Journal ArticleOPEN ACCESS

PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment

  • Kargbo R
ACS Medicinal Chemistry Letters (2023) 14(5) 541-542
DOI: 10.1021/acsmedchemlett.3c00113
N/ACitations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The anti-apoptotic BCL-2 protein family members, including BCL-2, BCL-XL, and MCL-1, have been established as promising therapeutic targets for cancer treatment, as evidenced by the FDA approval of...

Cite

CITATION STYLE

APA

Kargbo, R. B. (2023). PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment. ACS Medicinal Chemistry Letters, 14(5), 541–542. https://doi.org/10.1021/acsmedchemlett.3c00113

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free